SAB Biotherapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
SAB Biotherapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q3 2024.
  • SAB Biotherapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 40.3 %, a 45.5% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 40.3 -33.7 -45.5% Sep 30, 2024
Q2 2024 43.2 -28.4 -39.7% Jun 30, 2024
Q1 2024 51 -15.8 -23.6% Mar 31, 2024
Q4 2023 63.2 -1.97 -3.02% Dec 31, 2023
Q3 2023 74 -3.25 -4.21% Sep 30, 2023
Q2 2023 71.6 +4.35 +6.47% Jun 30, 2023
Q1 2023 66.8 +8.15 +13.9% Mar 31, 2023
Q4 2022 65.2 +19 +41.2% Dec 31, 2022
Q3 2022 77.3 +47.6 +161% Sep 30, 2022
Q2 2022 67.2 Jun 30, 2022
Q1 2022 58.6 Mar 31, 2022
Q4 2021 46.2 Dec 31, 2021
Q3 2021 29.7 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.